Semaglutide and NAION: The Vision-Loss Risk, Honestly

In 2024 and 2025, a worrying headline started circulating: semaglutide — the drug in Ozempic, Wegovy, and Rybelsus — might cause sudden, permanent vision loss. By mid-2025, both European regulators and the World Health Organization had weighed in. The signal is real, and it deserves to be taken seriously. But "real" and "common" are very different things, and the honest version of this story is mostly reassuring once you separate relative risk from absolute risk. Here is what NAION is, what the studies actually found, and how worried to be.

What NAION is

NAION stands for non-arteritic anterior ischemic optic neuropathy. In plain terms, it is a kind of "stroke" of the optic nerve: the blood supply to the front of the nerve is disrupted, and a portion of the nerve is damaged. It typically causes sudden, painless loss of part of the vision in one eye — often noticed on waking. The damage is usually permanent; there is no reliable treatment to reverse it. NAION is not unique to semaglutide — it is a known condition, more common in people with diabetes, high blood pressure, sleep apnea, and a particular "crowded" optic-disc anatomy. That background matters, because those same risk factors are common in people who take semaglutide.

How the alarm started

The signal came to wide attention through a 2024 study in JAMA Ophthalmology from a Harvard-affiliated eye center¹. Looking back through the records of patients seen at a neuro-ophthalmology practice, the researchers found that people prescribed semaglutide had a markedly higher rate of NAION than comparable patients on other diabetes or weight medicines — with hazard ratios of roughly 4-fold in the diabetes group and even higher in the overweight/obesity group¹.

Those numbers are striking, and they are what generated the headlines. But the authors themselves were careful: this was a single specialty center, the patients were already being seen for eye problems (not a general population), and a hazard ratio is a relative measure, not a count of how many people are actually affected. A study like this is excellent at detecting that a signal exists — and poor at telling you how common the event is in an ordinary patient.

What the larger studies found

When researchers went looking in much bigger, more general populations, the picture got both calmer and clearer. A 2025 cohort study in JAMA Network Open following tens of thousands of people on semaglutide or tirzepatide found a real but far more modest increase: a hazard ratio of about 1.76 for NAION². Crucially, it also reported the absolute numbers — and they are small. NAION occurred in about 0.04% of the treated group versus about 0.02% of the comparison group over two years². That is the difference between roughly 4 in 10,000 and 2 in 10,000 — a doubling in relative terms that is still a very rare event for any individual.

Other large analyses landed in the same neighborhood: a population-based study of people with type 2 diabetes also found an increased NAION risk with GLP-1 medicines³, a US veterans cohort examined new-onset NAION in semaglutide initiators⁴, and several 2025-26 systematic reviews and meta-analyses concluded that the evidence points to a real but small absolute increase in this rare event⁵⁶. A meta-analysis of randomized trial data likewise looked for optic-nerve and vision-threatening events across GLP-1 trials⁷. The consistent through-line: the relative risk is genuine, perhaps roughly a doubling, while the absolute risk to any one person stays very low.

What the regulators concluded

This is why the official conclusions matter so much. In June 2025, the European Medicines Agency's safety committee (PRAC) reviewed all the data and concluded that NAION is a very rare side effect of semaglutide medicines — using the regulatory term that means it may affect up to 1 in 10,000 people⁸. PRAC recommended that the product information for Ozempic, Rybelsus, and Wegovy be updated to list NAION as a side effect⁸. The World Health Organization echoed the assessment later that same month, on 27 June 2025, repeating the "very rare, up to 1 in 10,000" framing and advising that anyone with sudden or rapidly worsening vision on semaglutide contact a doctor without delay⁹. Notably, the regulators framed the underlying association in adults with type 2 diabetes as roughly a two-fold increase in risk⁸ — squarely in line with the larger cohort studies, not the higher single-center figures.

How worried should you be?

Honestly: aware, not alarmed. The case for taking it seriously is that NAION is irreversible — there is no fixing it once it happens — and the association is now accepted by major regulators, not dismissed as noise. The case for keeping it in proportion is that even after a relative doubling, the absolute risk remains on the order of a few per 10,000, against a backdrop where semaglutide also lowers cardiovascular risk in eligible patients (a benefit we cover in Wegovy and Ozempic heart benefits). For most people, the math still favors treatment — but it is a genuine, named risk to discuss with your prescriber, especially if you have already had NAION in one eye, or carry several of the background risk factors.

What to actually do

The practical guidance from the regulators is simple and worth following⁸⁹:

• •Know the warning sign: sudden, painless loss or blurring of vision, usually in one eye. If that happens, seek medical care promptly — do not wait to see if it passes.
• •If NAION is confirmed, semaglutide should generally be stopped, and the decision about restarting any GLP-1 medicine made carefully with your doctor.
• •Mention it at the start. If you have a history of NAION, optic-nerve problems, or poorly controlled diabetes and blood pressure, raise it before starting — it is part of an honest risk-benefit conversation.

This vision signal does not change the core safety picture of semaglutide so much as add one more rare, serious item to the list you weigh with a clinician. For the broader side-effect and dosing picture, see semaglutide dosing & side effects and our look at the gallbladder and kidney cautions. And if you and your doctor decide to stop, we cover what to expect in what happens if you stop semaglutide?. For the full picture of how the drug works and what the evidence shows, see our pillar, Semaglutide: how it works, results & side effects, and how the options compare in our best semaglutide guide.